CytoDyn (CYDY) Interest Coverage Ratio Growth (3y) (2015 - 2026)
Powered by 
Analysis
CytoDyn (CYDY) Interest Coverage Ratio Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -44.22% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 33.30% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -35.50% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 81.16% |
| 10 | CytoDyn | 257.86 Mn | 257.86 Mn | - | -241.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -241.80% |
| Feb 28, 2026 | -194.75% |
| Nov 30, 2025 | -69.21% |
| Aug 31, 2025 | -104.05% |
| May 31, 2025 | 30.17% |
| Feb 28, 2025 | -58.10% |
| Nov 30, 2024 | -22.99% |
| Aug 31, 2024 | 184.78% |
| May 31, 2024 | -124.82% |
| Feb 29, 2024 | 13.16% |
| Nov 30, 2023 | -17.10% |
| Aug 31, 2023 | 7.43% |
| May 31, 2023 | 24.57% |
| Feb 28, 2023 | 41.08% |
| Nov 30, 2022 | -19.08% |
| Aug 31, 2022 | 34.32% |
| May 31, 2022 | -76.72% |
| Feb 28, 2022 | 58.34% |
| Nov 30, 2021 | 42.62% |
| Aug 31, 2021 | 77.06% |